Evoke Pharma, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Evoke Pharma, Inc., a specialty pharmaceutical firm, concentrates its efforts on developing and bringing to market therapies for digestive system ailments. Its flagship product is Gimoti, an innovative metoclopramide nasal spray, which has received approval for alleviating symptoms associated with acute and recurring diabetic gastroparesis in adults. This unique formulation delivers metoclopramide systemically via the nasal passages, offering an alternative for patients who struggle with oral medications due to delayed gastric emptying or frequent vomiting. The company engages with gastroenterologists, internal medicine specialists, primary care doctors, and other healthcare providers to promote its treatment. Founded in 2007, Evoke Pharma maintains its corporate headquarters in Solana Beach, California. The company has demonstrated significant commercial progress, reporting substantial revenue growth for Gimoti in recent quarters. Furthermore, a new U.S. patent extends Gimoti's market exclusivity until November 2038, and a definitive agreement for Evoke Pharma's acquisition by QOL Medical is expected to conclude by the end of 2025.
Evoke shares jump 16% as William Hill owner agrees £243m takeover by Bally's Intralot
Evoke Agrees to $326 Million Takeover Bid From Bally's Intralot
William Hill UK owner Evoke agrees $326 million takeover by Bally's Intralot
William Hill owner Evoke in talks with Ball's Intralot about potential takeover
William Hill UK owner Evoke confirms $304 million takeover bid from Bally's Intralot
William Hill owner Evoke reports strongest quarter of the year, sale process ongoing
Deutsche Bank downgrades Evoke and Rank as gaming outlook resets
Evoke Pharma and QOL Medical Announce Expiration of Tender Offer
William Hill owner Evoke puts business up for sale as gambling taxes weigh
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—TRUE, BRY, EVOK, and FSFG
Entain, Evoke and Flutter warn of jobs cuts and illegal gambling due to Budget tax hike
Evoke assesses Italian unit sale amid tax concerns ahead of budget, Sky News reports
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Evoke Pharma, Inc. (NASDAQ: EVOK)
Shareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc. is obtaining a Fair Price for its Public Shareholders
EVOK Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Evoke Pharma, Inc. is Fair to Shareholders
MAI Capital Management Announces Expanded Office of Managing Partners Appointments Following Strategic Acquisition of Evoke Advisors
William Hill owner Evoke threatens betting shop closures if taxes go up
Evoke Advisors Ranked No. 1 on Forbes' ‘America's Top RIA Firms' List for Fourth Consecutive Year
MAI Capital Management Announces Strategic Partnership with Evoke Advisors
Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship